LabVantage Release Labvantage 8
News Feb 22, 2016
LabVantage Solutions has announced the release of the latest, most powerful version of its solution, LabVantage 8. A configurable, web-based solution, LabVantage is used by companies worldwide to automate their laboratory processes and strategically transform their businesses.
The newest version includes new capabilities that enable laboratories to operate with even greater efficiency, effectiveness and quality.
“Among the many advances in LabVantage 8, you will see a new user interface—developed with extensive customer input—that greatly enhances usability,” said Peter Bailey, Chief Executive Officer at LabVantage Solutions.
“As we celebrate our 35th year of leadership in the LIMS industry, the introduction of LabVantage 8 is a testament to the innovation that we have brought, and will continue to bring, to the market. Our goal is simple: we want our customers to have the type of solution that helps them grow their businesses.”
In addition to a new user interface, LabVantage 8 includes several new enhancements designed to increase efficiency, including an improved design for viewing and managing critical data making it quicker to access and intuitive to use. A new scheduler interface features a calendar view, schedule randomization and local time zone support.
Other highlights include a new, end-to-end formulations solution that manages compound recipes. For the Biobanking industry, LabVantage 8 incorporates a new accessioning feature that greatly simplifies and integrates sample allocation, as well as a consent management feature that enforces compliance in the subject’s sample usage for studies.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Deceased Data: Should Your Online Remains Be Treated Like Physical Remains?News
In 2018, your death doesn't just leave behind a body. It leaves behind a huge online footprint - your digital remains. A new study asks whether these remains should be treated and respected as a corpse would, and whether museums may provide a blueprint for the preservation process.READ MORE